Literature DB >> 1974342

Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.

A Berchuck1, G Rodriguez, A Kamel, J T Soper, D L Clarke-Pearson, R C Bast.   

Abstract

Monoclonal antibodies were used to localize immunohistochemically epidermal growth factor receptor and HER-2/neu in normal and neoplastic frozen tissue samples from the lower genital tract of women. In squamous epithelia of the cervix, vulva, and vagina, epidermal growth factor receptor and HER-2/neu both were expressed most strongly by basal keratinocytes. Expression of both of these cell surface molecules decreased as cells underwent differentiation toward the mucosal surface. In contrast, both epidermal growth factor receptor and HER-2/neu were expressed throughout the entire thickness of the epithelium by undifferentiated squamous cells in squamous metaplasia, raised condyloma, and carcinoma in situ. In 34 squamous cancers of the cervix, vulva, and vagina, all malignant cells were found to have moderate to heavy staining for epidermal growth factor receptor. Staining of 33 of these cancers for HER-2/neu was light, although one patient who presented with distant metastases had heavy staining for HER-2/neu. These data suggest that although overexpression of HER-2/neu in squamous cancers of the lower genital tract is a rare event, it may be associated with aggressive biologic behavior.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974342

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  16 in total

1.  Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions.

Authors:  M A Adelsman; B K Huntley; N J Maihle
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 2.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

3.  CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.

Authors:  Sofia Lérias; Susana Esteves; Fernanda Silva; Mário Cunha; Daniela Cochicho; Luís Martins; Ana Félix
Journal:  Mod Pathol       Date:  2019-12-16       Impact factor: 7.842

Review 4.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

5.  Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.

Authors:  R J Hale; C H Buckley; H Fox; J Williams
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

6.  Arecoline induced disruption of expression and localization of the tight junctional protein ZO-1 is dependent on the HER 2 expression in human endometrial Ishikawa cells.

Authors:  Sarbani Giri; Kevin M Poindexter; Shyam N Sundar; Gary L Firestone
Journal:  BMC Cell Biol       Date:  2010-07-06       Impact factor: 4.241

7.  Prognostic value of epidermal growth factor receptor expression in cervical carcinoma.

Authors:  R J Hale; C H Buckley; W J Gullick; H Fox; J Williams; F L Wilcox
Journal:  J Clin Pathol       Date:  1993-02       Impact factor: 3.411

8.  Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.

Authors:  B L King; D Carter; H G Foellmer; B M Kacinski
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

Review 9.  Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

Authors:  Chong Hyun Suh; Sree H Tirumani; Abhishek Keraliya; Kyung Won Kim; Nikhil H Ramaiya; Atul B Shinagare
Journal:  Br J Radiol       Date:  2016-07-12       Impact factor: 3.039

Review 10.  Chemotherapy of vulvar cancer: a review.

Authors:  Gunter Deppe; Ismail Mert; Jimmy Belotte; Ira S Winer
Journal:  Wien Klin Wochenschr       Date:  2013-03-22       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.